Figma Shares Indicated To Open $105/$110
XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB, (TASE:XTLB).TA) announced Monday the postponement of its annual and extraordinary shareholders’ meeting, which had been scheduled for Monday, after legal quorum requirements were not met. The company stated that the meeting will be reconvened on July 28, 2025, at 4:00 p.m. Israel Standard Time.
The announcement was made in a press release and disclosed in a filing with the U.S. Securities and Exchange Commission. XTL Biopharmaceuticals, based in Ramat Gan, Israel, reported that the postponement follows the procedures outlined in the meeting’s convening notice.
XTL Biopharmaceuticals is an intellectual property portfolio company and holds 100% of The Social Proxy Ltd., a web data company. The company has also sublicensed an IP portfolio related to hCDR1 for the treatment of lupus disease (SLE).
No further details regarding the agenda of the postponed meeting or the issues requiring shareholder approval were provided in the filing.
This information is based on a press release statement and a filing with the Securities and Exchange Commission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.